Published in Biochim Biophys Acta on April 23, 2010
The Concise Guide to PHARMACOLOGY 2013/14: nuclear hormone receptors. Br J Pharmacol (2013) 1.70
miR-33 controls the expression of biliary transporters, and mediates statin- and diet-induced hepatotoxicity. EMBO Mol Med (2012) 1.54
Increased activation of the Wnt/β-catenin pathway in spontaneous hepatocellular carcinoma observed in farnesoid X receptor knockout mice. J Pharmacol Exp Ther (2011) 1.36
Choline metabolism provides novel insights into nonalcoholic fatty liver disease and its progression. Curr Opin Gastroenterol (2012) 1.17
Hepatocyte-specific deletion of farnesoid X receptor delays but does not inhibit liver regeneration after partial hepatectomy in mice. Hepatology (2012) 1.02
Genome-wide multi-omics profiling of colorectal cancer identifies immune determinants strongly associated with relapse. Front Genet (2013) 0.99
Role of bile acids in liver injury and regeneration following acetaminophen overdose. Am J Pathol (2013) 0.99
Getting the mOST from OST: Role of organic solute transporter, OSTalpha-OSTbeta, in bile acid and steroid metabolism. Biochim Biophys Acta (2010) 0.97
Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One (2012) 0.96
Bile salt export pump is dysregulated with altered farnesoid X receptor isoform expression in patients with hepatocellular carcinoma. Hepatology (2013) 0.91
Simultaneous non-negative matrix factorization for multiple large scale gene expression datasets in toxicology. PLoS One (2012) 0.87
A tea catechin, epigallocatechin-3-gallate, is a unique modulator of the farnesoid X receptor. Toxicol Appl Pharmacol (2011) 0.86
Muscarinic receptor signaling in colon cancer. Cancers (Basel) (2011) 0.86
The impact of farnesoid X receptor activation on intestinal permeability in inflammatory bowel disease. Can J Gastroenterol (2012) 0.86
An atherogenic diet decreases liver FXR gene expression and causes severe hepatic steatosis and hepatic cholesterol accumulation: effect of endurance training. Eur J Nutr (2012) 0.82
Fatty liver accompanies an increase in lactobacillus species in the hind gut of C57BL/6 mice fed a high-fat diet. J Nutr (2013) 0.81
Farnesoid X receptor, the bile acid sensing nuclear receptor, in liver regeneration. Acta Pharm Sin B (2015) 0.81
Postnatal Deletion of Fat Storage-inducing Transmembrane Protein 2 (FIT2/FITM2) Causes Lethal Enteropathy. J Biol Chem (2015) 0.81
Bile acid nuclear receptor FXR and digestive system diseases. Acta Pharm Sin B (2015) 0.81
Src-mediated cross-talk between farnesoid X and epidermal growth factor receptors inhibits human intestinal cell proliferation and tumorigenesis. PLoS One (2012) 0.79
Bile acids regulate intestinal cell proliferation by modulating EGFR and FXR signaling. Am J Physiol Gastrointest Liver Physiol (2015) 0.79
Bile acids regulate nuclear receptor (Nur77) expression and intracellular location to control proliferation and apoptosis. Mol Cancer Res (2014) 0.79
The interaction between HCV and nuclear receptor-mediated pathways. Pharmacol Ther (2011) 0.78
Bile acids promote diethylnitrosamine-induced hepatocellular carcinoma via increased inflammatory signaling. Am J Physiol Gastrointest Liver Physiol (2016) 0.77
Obeticholic acid, a synthetic bile acid agonist of the farnesoid X receptor, attenuates experimental autoimmune encephalomyelitis. Proc Natl Acad Sci U S A (2016) 0.77
Novel bile acid therapeutics for the treatment of chronic liver diseases. Therap Adv Gastroenterol (2016) 0.76
Sodium taurocholate cotransporting polypeptide mediates dual actions of deoxycholic acid in human hepatocellular carcinoma cells: enhanced apoptosis versus growth stimulation. J Cancer Res Clin Oncol (2013) 0.76
Circulating MicroRNAs as Biomarkers in Biliary Tract Cancers. Int J Mol Sci (2016) 0.76
Farnesoid X Receptor Activation Attenuates Intestinal Ischemia Reperfusion Injury in Rats. PLoS One (2017) 0.75
Impact of global Fxr deficiency on experimental acute pancreatitis and genetic variation in the FXR locus in human acute pancreatitis. PLoS One (2014) 0.75
Bile components and lecithin supplemented to plant based diets do not diminish diet related intestinal inflammation in Atlantic salmon. BMC Vet Res (2016) 0.75
Effect of Liver Disease on Hepatic Transporter Expression and Function. J Pharm Sci (2017) 0.75
Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. Gastroenterology (2011) 6.36
Colonic stenting versus emergency surgery for acute left-sided malignant colonic obstruction: a multicentre randomised trial. Lancet Oncol (2011) 3.68
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Special situations. J Crohns Colitis (2009) 3.66
Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Inflamm Bowel Dis (2007) 2.89
The gene product Murr1 restricts HIV-1 replication in resting CD4+ lymphocytes. Nature (2003) 2.63
Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut (2011) 2.57
Early endoscopic retrograde cholangiopancreatography versus conservative management in acute biliary pancreatitis without cholangitis: a meta-analysis of randomized trials. Ann Surg (2008) 2.52
Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions. Hepatology (2012) 2.39
Effect of a retrograde-viewing device on adenoma detection rate during colonoscopy: the TERRACE study. Gastrointest Endosc (2010) 2.38
Nasobiliary drainage induces long-lasting remission in benign recurrent intrahepatic cholestasis. Hepatology (2006) 2.37
Stent versus gastrojejunostomy for the palliation of gastric outlet obstruction: a systematic review. BMC Gastroenterol (2007) 2.26
Long-term exclusive zinc monotherapy in symptomatic Wilson disease: experience in 17 patients. Hepatology (2009) 2.25
Efficacy and safety of the new WallFlex enteral stent in palliative treatment of malignant gastric outlet obstruction (DUOFLEX study): a prospective multicenter study. Gastrointest Endosc (2009) 2.23
Safety of endoscopic removal of self-expandable stents after treatment of benign esophageal diseases. Gastrointest Endosc (2013) 2.22
In vitro evaluation of the radial and axial force of self-expanding esophageal stents. Endoscopy (2013) 2.18
Patients with Barrett's esophagus perceive their risk of developing esophageal adenocarcinoma as low. Gastrointest Endosc (2007) 2.18
Lysophosphatidic acid is a potential mediator of cholestatic pruritus. Gastroenterology (2010) 2.18
Small gallstones are associated with increased risk of acute pancreatitis: potential benefits of prophylactic cholecystectomy? Am J Gastroenterol (2005) 2.08
Single-dose brachytherapy versus metal stent placement for the palliation of dysphagia from oesophageal cancer: multicentre randomised trial. Lancet (2004) 2.06
Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nat Genet (2004) 2.04
Blood lipid and lipoprotein concentrations and colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition. Gut (2011) 2.03
Sustained clinical benefit and tolerability of methotrexate monotherapy after thiopurine therapy in patients with Crohn's disease. Clin Gastroenterol Hepatol (2013) 2.00
Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation. Inflamm Bowel Dis (2011) 1.97
Surgical gastrojejunostomy or endoscopic stent placement for the palliation of malignant gastric outlet obstruction (SUSTENT study): a multicenter randomized trial. Gastrointest Endosc (2009) 1.97
Neoplasia yield and colonoscopic workload of surveillance regimes for colorectal cancer in colitis patients: a retrospective study comparing the performance of the updated AGA and BSG guidelines. Inflamm Bowel Dis (2013) 1.96
A prospective cohort study evaluating a novel colonoscopy platform featuring full-spectrum endoscopy. Endoscopy (2013) 1.95
Removable self-expanding plastic esophageal stent as a continuous, non-permanent dilator in treating refractory benign esophageal strictures: a prospective two-center study. Am J Gastroenterol (2008) 1.92
Reduced expression of ATP7B affected by Wilson disease-causing mutations is rescued by pharmacological folding chaperones 4-phenylbutyrate and curcumin. Hepatology (2009) 1.92
A novel role for XIAP in copper homeostasis through regulation of MURR1. EMBO J (2003) 1.90
Body mass index and the risk for Crohn's disease and ulcerative colitis: data from a European Prospective Cohort Study (The IBD in EPIC Study). Am J Gastroenterol (2013) 1.77
Folding defects in P-type ATP 8B1 associated with hereditary cholestasis are ameliorated by 4-phenylbutyrate. Hepatology (2010) 1.76
Electrocautery therapy for refractory anastomotic strictures of the esophagus. Gastrointest Endosc (2006) 1.76
Intestinal barrier dysfunction in a randomized trial of a specific probiotic composition in acute pancreatitis. Ann Surg (2009) 1.76
Prediagnostic circulating vitamin D levels and risk of hepatocellular carcinoma in European populations: a nested case-control study. Hepatology (2014) 1.75
Outcome of surgical treatment for early adenocarcinoma of the esophagus or gastro-esophageal junction. Virchows Arch (2005) 1.74
Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease. Gut (2011) 1.74
Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 3: special situations. J Crohns Colitis (2012) 1.71
ERCP as an outpatient treatment: a review. Gastrointest Endosc (2008) 1.68
Biomarkers of oxidative stress and risk of developing colorectal cancer: a cohort-nested case-control study in the European Prospective Investigation Into Cancer and Nutrition. Am J Epidemiol (2012) 1.65
High lifetime risk of cancer in primary sclerosing cholangitis. J Hepatol (2008) 1.64
Characterization of mutations in ATP8B1 associated with hereditary cholestasis. Hepatology (2004) 1.64
Esophageal stents with antireflux valve for tumors of the distal esophagus and gastric cardia: a randomized trial. Gastrointest Endosc (2004) 1.64
Serological markers predict inflammatory bowel disease years before the diagnosis. Gut (2012) 1.64
Aneuploidy and overexpression of Ki67 and p53 as markers for neoplastic progression in Barrett's esophagus: a case-control study. Am J Gastroenterol (2009) 1.60
Benign recurrent intrahepatic cholestasis type 2 is caused by mutations in ABCB11. Gastroenterology (2004) 1.60
Is complicated gallstone disease preceded by biliary colic? J Gastrointest Surg (2008) 1.59
Stent placement or brachytherapy for palliation of dysphagia from esophageal cancer: a prognostic model to guide treatment selection. Gastrointest Endosc (2005) 1.58
Relapse is almost universal after withdrawal of immunosuppressive medication in patients with autoimmune hepatitis in remission. J Hepatol (2012) 1.58
Small gallstones, preserved gallbladder motility, and fast crystallization are associated with pancreatitis. Hepatology (2005) 1.58
Cardiovascular and gastrointestinal outcomes in clopidogrel users on proton pump inhibitors: results of a large Dutch cohort study. Am J Gastroenterol (2010) 1.58
Plasma alkylresorcinols, biomarkers of whole-grain wheat and rye intake, and incidence of colorectal cancer. J Natl Cancer Inst (2013) 1.57
Ingestion of acid and alkaline agents: outcome and prognostic value of early upper endoscopy. Gastrointest Endosc (2004) 1.57
Ursodeoxycholic acid exerts no beneficial effect in patients with symptomatic gallstones awaiting cholecystectomy. Hepatology (2006) 1.54
IBS-like symptoms in patients with inflammatory bowel disease in remission; relationships with quality of life and coping behavior. Dig Dis Sci (2004) 1.53
Common variants at the MHC locus and at chromosome 16q24.1 predispose to Barrett's esophagus. Nat Genet (2012) 1.52
Bile acid-stimulated expression of the farnesoid X receptor enhances the immune response in Barrett esophagus. Am J Gastroenterol (2008) 1.51
Fully covered self-expandable metal stents (SEMS), partially covered SEMS and self-expandable plastic stents for the treatment of benign esophageal ruptures and anastomotic leaks. BMC Gastroenterol (2012) 1.50
Rising incidence of clinically evident Barrett's oesophagus in The Netherlands: a nation-wide registry of pathology reports. Scand J Gastroenterol (2007) 1.49
Efficacy and safety of biodegradable stents for refractory benign esophageal strictures: the BEST (Biodegradable Esophageal Stent) study. Gastrointest Endosc (2010) 1.49
The H1069Q mutation in ATP7B is associated with late and neurologic presentation in Wilson disease: results of a meta-analysis. J Hepatol (2004) 1.49
A fully-covered stent (Alimaxx-E) for the palliation of malignant dysphagia: a prospective follow-up study. Gastrointest Endosc (2009) 1.47
Human copper transporter 2 is localized in late endosomes and lysosomes and facilitates cellular copper uptake. Biochem J (2007) 1.47
Reduced medication dependency and improved symptoms and quality of life 12 months after enteryx implantation for gastroesophageal reflux. J Clin Gastroenterol (2005) 1.46
No beneficial effects of amantadine in treatment of chronic hepatitis C patients. Dig Liver Dis (2009) 1.46
Two mass-spectrometric techniques for quantifying serine enantiomers and glycine in cerebrospinal fluid: potential confounders and age-dependent ranges. Clin Chem (2008) 1.45
Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology (2009) 1.45
Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res (2004) 1.44
Ultrasound, computed tomography, or the combination for the detection of supraclavicular lymph nodes in patients with esophageal or gastric cardia cancer: a comparative study. J Surg Oncol (2007) 1.42
Nurses working in GI and endoscopic practice: a review. Gastrointest Endosc (2007) 1.42
Population-based epidemiology, malignancy risk, and outcome of primary sclerosing cholangitis. Hepatology (2013) 1.39
Simulation of a colorectal polypoid lesion--a pilot porcine model. Gastrointest Endosc (2008) 1.39
Optimizing screening for tuberculosis and hepatitis B prior to starting tumor necrosis factor-α inhibitors in Crohn's disease. Dig Dis Sci (2013) 1.38
Familial cholestasis: progressive familial intrahepatic cholestasis, benign recurrent intrahepatic cholestasis and intrahepatic cholestasis of pregnancy. Best Pract Res Clin Gastroenterol (2010) 1.35
New design esophageal stents for the palliation of dysphagia from esophageal or gastric cardia cancer: a randomized trial. Am J Gastroenterol (2007) 1.34
Plasma antibodies to oral bacteria and risk of pancreatic cancer in a large European prospective cohort study. Gut (2012) 1.32
Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis (2013) 1.31
ATP8B1 is essential for maintaining normal hearing. Proc Natl Acad Sci U S A (2009) 1.30
Biochemical characterization and subcellular localization of human copper transporter 1 (hCTR1). Biochem J (2002) 1.29
The ubiquitously expressed MURR1 protein is absent in canine copper toxicosis. J Hepatol (2003) 1.29
Characterization of COMMD protein-protein interactions in NF-kappaB signalling. Biochem J (2006) 1.27
Chemotherapy followed by surgery versus surgery alone in patients with resectable oesophageal squamous cell carcinoma: long-term results of a randomized controlled trial. BMC Cancer (2011) 1.27
Distinct Wilson's disease mutations in ATP7B are associated with enhanced binding to COMMD1 and reduced stability of ATP7B. Gastroenterology (2007) 1.23
Coordinate regulation of gallbladder motor function in the gut-liver axis. Hepatology (2008) 1.22